Henry Schein Inc.
05/05/2026 | Press release | Distributed by Public on 05/05/2026 04:15
Business/Financial Results (Form 8-K)
-1-
more
FOR IMMEDIATE RELEASE
HENRY SCHEIN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
●
Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS inQ1 2025
●
Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP dilutedEPS in Q1 2025
●
Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and AdjustedEBITDA
●
Confirming that value creation initiatives are expected to deliver over $200 million of operatingincome
improvement over the next few years, with $125 million run-rate by year-end2026
MELVILLE, N.Y.,May 5, 2026 -
Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care
solutions to office-based dental and medical practitioners, today reported financial resultsfor the first quarter ended March
28, 2026.
"I am pleased with our strong first quarter results that reflect continuingmomentum from the second half of last year
as we grow market share and expand gross margins. Our growth outlook,combined with the progress made on value-creation
initiatives and a strong start to the year, reinforcesmy confidence that we will deliver on our 2026 financial guidance,"said
Fred Lowery,Chief Executive Officer of Henry Schein."I am committed to the Company's goal of achieving greater than
$200 million of annual operating income improvement within the nextfew years, with a $125 million run-rate by the end of
2026. These initiatives, along with continued execution of our strategicplan, will contribute to us achieving high-single digit
to low-double digit earnings growth in the coming years."
"Over the last two months as I have immersed myself in the businessand spoken with customers, suppliers and
employees, it is clear that Henry Schein has great assets with adifferentiated platform to serve as a trusted partner to
healthcare practitionersworldwide. As we look ahead, I'm excited by the significantopportunities to accelerate growth
through the use of technology,improve operational execution, and becomea more agile company," added Mr. Lowery.
First Quarter 2026Financial Results
●
Totalnet sales
for the quarter were $3.4 billion,an increase of 6.3% compared to the first quarter of 2025 and
reflects 2.5% internal sales growth, 0.7% sales growth from acquisitions, anda 3.1% increase resulting from foreign
currency exchange. First quarter sales growth is detailed in Exhibit A
1
.
●
Global Distribution and Value-Added Services sales
for the quarter increased 6.1%, and reflects 2.5% internal
sales growth, 0.6% sales growth from acquisitions, and a 3.0% increaseresulting from foreign currency exchange
compared with the first quarter of 2025. The main components are:
●
Global Dental Distribution merchandise sales
for the quarter increased 9.0%, and by 3.0% internal sales
growth, compared with the first quarter of 2025, with continuing strongmomentum in the U.S.
-2-
more
●
Global Dental Distribution equipment sales
for the quarter increased 8.6%, and by 3.5% internal sales
growth, compared with the first quarter of 2025.
●
Global Medical Distribution sales
for the quarter increased 1.7%, and by 1.3% internal sales growth,
compared with the first quarter of 2025.
●
Global Value-Added Services sales
for the
quarter increased 10.6%, and by 7.8% internal sales growth,
compared with the first quarter of 2025.
●
Global Specialty Products sales
for the quarter increased 8.1%, and by 1.7%internal sales growth, 1.7% sales
growth from acquisitions, and a 4.7% increase resulting fromforeign currency exchange, compared with the first
quarter of 2025.
●
Global Technology sales
for the quarter increased 7.0%, and reflects 6.9% internal sales growth, 1.3%sales
decrease due to a business disposal,and a 1.4% increase resulting from foreign currency exchange,compared with
the first quarter of 2025.
●
GAAP net income
2
for the quarter was $107 million, or $0.92 per diluted share
4
, and compares with first-quarter
2025 GAAP net income of $110 million, or $0.88 per diluted share.
●
Non-GAAP net income
2
for the quarter was $153 million, or $1.32
per diluted share
4
, and compares with first-
quarter 2025 non-GAAP net income of $143 million, or $1.15 per dilutedshare.
●
Adjusted EBITDA
3
for the quarter was $289 million and compareswith first-quarter 2025Adjusted EBITDA of
$259 million.
●
In the first quarter of 2026, the Company acquired a controlling interestin its S.I.N. distributor in the U.S. to enhance
its position in the value implant market and support its business integrationstrategy.This transaction resulted in a
remeasurement gain of $11 million.
Share Repurchases
During the first quarter of 2026, the Company repurchased approximately1.6 million shares of common stock at an
average price of $77.64 per share for a total of $125 million.
At the end of the quarter,Henry Schein had $655 million authorized and available for future stockrepurchases.
2026 Financial Guidance
Henry Schein today reaffirmed its financial guidance for 2026. Guidance is for currentcontinuing operations and
does not include the impact of restructuring expenses and related costs, amortizationexpense of acquired intangible assets,
the impairment of intangible assets,changes in contingent consideration,costs associated with shareholder advisory matters,
select implementation-related costs supporting value creationinitiatives,and litigation settlements. This guidance also
assumes that foreign currency exchange rates remain generally consistent withcurrent levels.
●
2026 non-GAAP diluted EPS attributable to Henry Schein, Inc.is unchanged and expected to be $5.23 to $5.37.
-3-
more
●
2026 total sales growth is unchanged and expected to be approximately 3%to 5% over 2025.
●
2026 Adjusted EBITDA
3
is unchanged and expected to grow mid-single digits compared with 2025.
Adjustments to 2026 GAAP Net Income and Diluted EPS
The Company is providing guidance for 2026 diluted EPS and for 2026Adjusted EBITDA on a non-GAAP basis, as
noted above. The Company is not providing a reconciliation of its 2026 non-GAAPdiluted EPS guidance to its projected
2026 diluted EPS prepared on a GAAP basis, or its 2026Adjusted EBITDA guidance to net income prepared on a GAAP
basis. This is because the Company is unable to provide withoutunreasonable effort an estimate of restructuring expenses
and related costs, including its ongoing value-creation initiatives, andthe corresponding tax effect, which will be included in
the Company's 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide thisreconciliation is
due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude,financial impact and timing of related
costs.
Management does not believe these items are representative of the Company's underlying business performance.For
the same reasons, the Company is unable to address the probable significanceof the unavailable information, which could be
material to future results.
First-Quarter 2026 Conference Call Webcast
The Company will hold a conference call to discuss first-quarter 2026 financialresults today, beginning at 8:00 a.m.
Eastern time. Individual investors are invited to listen to theconference call through Henry Schein's website by visiting
https://investor.henryschein.com/webcasts. In addition, a replay will be available beginning shortly after the call hasended
for a period of one week.
The Company will be posting slides that provide a summary of its first-quarter2026financial results on its website at
https://investor.henryschein.com/financials/quarterly-results/.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health careprofessionals powered by a network of
people and technology. With more than 25,000 TeamSchein Members worldwide, the Company's network of trusted
advisors provides more than 1 million customers globally with morethan 300 valued solutions that help improve operational
success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and
medical practitioners work more efficiently so they can provide quality care moreeffectively. These solutions also support
dental laboratories, government and institutional health care clinics, as wellas other alternate care sites.
Henry Schein operates through a centralized and automated distributionnetwork, with a selection of more than
300,000 branded products and Henry Schein corporate brand productsin our main distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville,
N.Y.,and has operations or affiliates in 34 countries and territories. The Company's sales reached$13.2 billion in 2025, and
have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a publiccompany in 1995.
-4-
more
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein,
Instagram.com/HenrySchein,and @HenrySchein on X.
Henry Schein Inc. published this content on May 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 05, 2026 at 10:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]